PharmGKB summary: cyclosporine and tacrolimus pathways.
Departments of aGenetics bBioengineering, Stanford University, Stanford, California cDepartment of Pharmaceutical Sciences, School of Pharmacy dDepartment of Pathology, School of Medicine, Starzl Transplantation Institute, University of Pittsburgh, Pittsburgh, Pennsylvania, USA eSchool of Pharmacy, University of Queensland, Brisbane, Australia.
Julia M
JM
Barbarino
Christine E
CE
Staatz
Raman
R
Venkataramanan
Teri E
TE
Klein
Russ B
RB
Altman
D018435:ATP Binding Cassette Transporter, Subfamily B; D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1 / Q000235:genetics; D019703:Calcineurin / Q000235:genetics / Q000378:metabolism; D016572:Cyclosporine / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use; D051544:Cytochrome P-450 CYP3A / Q000235:genetics; D014644:Genetic Variation; D006084:Graft Rejection / Q000188:drug therapy* / Q000517:prevention & control*; D006801:Humans; D007166:Immunosuppressive Agents / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use; D020935:MAP Kinase Signaling System; D016377:Organ Transplantation; D010597:Pharmacogenetics; D011110:Polymorphism, Genetic; D016559:Tacrolimus / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use; D053773:Transforming Growth Factor beta1 / Q000235:genetics
C513055:ABCB1 protein, human; D018435:ATP Binding Cassette Transporter, Subfamily B; D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1; D007166:Immunosuppressive Agents; C508960:TGFB1 protein, human; D053773:Transforming Growth Factor beta1; D016572:Cyclosporine; C510164:CYP3A5 protein, human; D051544:Cytochrome P-450 CYP3A; C510163:CYP3A4 protein, human; D019703:Calcineurin; D016559:Tacrolimus